Drug Profile


Alternative Names: ADXS-PSA; ADXS31-142; Live attenuated Listeria-based vaccines for cancer - Advaxis; Lovaxin P; Prostate cancer vaccine - Advaxis

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator Advaxis
  • Developer Advaxis; Merck & Co
  • Class Cancer vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 20 Oct 2016 Advaxis initiates enrolment in the KEYNOTE-046 trial for Prostate cancer (Monotherapy, Hormone refractory, Metastatic disease) in USA (NCT02325557)
  • 26 Aug 2015 Advaxis Immunotherapies and Knight Therapeutics enter into a license agreement to commercialise Advaxis's products, including ADXS PSA in Canada
  • 05 Aug 2015 Advaxis plans a phase I/II, CARAVAN trial for Prostate cancer (Metastatic, Treatment-resistant) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top